Close Menu

Silence

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

Overview of key RNAi-based therapeutics currently in human trials

According to Silence, the patent's amended claims "no longer cover other chemical modifications and molecular designs not used by Silence and which therefore do not have an impact on Silence’s core business."

Silence said that it "expects the proposed transaction to be treated as a reverse takeover … [and will be] subject to due diligence and would be conditional upon shareholder approval."

Under the terms of the deal, Silence will “demonstrate the functional delivery” of its proprietary siRNA molecules, in combination with its in-house AtuPlex delivery technology, to certain undisclosed targets.

Preparations for the clinical study — the company's first — contributed to a 40 percent rise in research and development spending in 2008, which drove a 45 percent increase in net losses.

Thomas Cech, Jeffery Vick

Pages

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.